Animal product manufacturer Telsol bought by Bimeda

YORKSHIRE firm Telsol, which manufactures and markets a range of large animal boluses that deliver benefits to livestock, has been acquired by Bimeda.
According to Leeds-based Telsol, the boluses (tablets used in veterinary medicine) are different to others on the market as they are based on a unique delivery technology, developed by Dr Stewart Telfer in conjunction with the University of Leeds and Pilkington Glass. 

Bimeda Animal Health, with its headquarters in Dublin, develops and manufactures veterinary and animal health products which are sold across five continents in more than 75 countries. The company’s main focus is the development of high quality preventatives and treatments primarily focused on livestock, poultry and horses.
Ian Simington, CEO, Bimeda Europe, said, “Telsol’s boluses with their proven differentiated benefits are a good fit for the Bimeda ruminant product range and enhance our offer to customers. We look forward to working with the team at Telsol to further develop the business.”

Telsol was originally a spin-out from the department of Animal Physiology and Nutrition at Leeds University in 1996. 
The negotiations for both the original spin-put and the sale to Bimeda were led by non-executive director, Colin Glass, senior partner of Winburn Glass Norfolk chartered accountants.

Mr Glass said: “It has been a pleasure working with my dedicated co-directors, Dr Stewart Telfer, Sheila Telfer and Dr Brian Algar over the past 15 years and we all believe the future for Telsol and its innovative products will be greatly enhanced through the acquisition of the company by Bimeda.” 
The individual shareholders, excluding the University of Leeds, were advised on the sale of their shares by Rachel Neems of Leeds law firm Clarion.